Motixafortide for Adenocarcinoma

Phase-Based Progress Estimates
Adenocarcinoma+2 MoreMotixafortide - Drug
All Sexes
What conditions do you have?

Study Summary

This trial is testing a new combination of chemotherapy drugs and immunotherapy to see if it's effective in treating pancreatic cancer.

Eligible Conditions
  • Adenocarcinoma
  • Pancreatic Adenocarcinoma
  • Pancreatic Cancer

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 5 Secondary · Reporting Duration: Up to 5 years

16 weeks
Disease Control Rate
Overall Response Rate (Complete Response (CR) + Partial Response (PR))
Up to 5 years
Duration of Clinical Benefit
Incidence of Treatment Related Toxicities
Median Overall Survival
Median Progression Free Survival

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Trial Design

1 Treatment Group

Motixafortide, Cemiplimab, Gemcitabine, Nab-Paclitaxel
1 of 1

Experimental Treatment

10 Total Participants · 1 Treatment Group

Primary Treatment: Motixafortide · No Placebo Group · Phase 2

Motixafortide, Cemiplimab, Gemcitabine, Nab-PaclitaxelExperimental Group · 4 Interventions: Motixafortide, Cemiplimab, Gemcitabine, Nab paclitaxel · Intervention Types: Drug, Drug, Drug, Drug
First Studied
Drug Approval Stage
How many patients have taken this drug
FDA approved
FDA approved

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to 5 years

Who is running the clinical trial?

Regeneron PharmaceuticalsIndustry Sponsor
546 Previous Clinical Trials
199,805 Total Patients Enrolled
1 Trials studying Adenocarcinoma
98 Patients Enrolled for Adenocarcinoma
Gulam ManjiLead Sponsor
3 Previous Clinical Trials
84 Total Patients Enrolled
2 Trials studying Adenocarcinoma
41 Patients Enrolled for Adenocarcinoma
Gulam Manji, MD,PhD3.33 ReviewsPrincipal Investigator - Columbia University
Columbia University
4Patient Review
Dr Manji is a great oncologist, but can be forgetful when it comes to scheduling and other responsibilities. I would still recommend him, as long as you are willing to be proactive.

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
Cytologic or histologic proof of pancreas adenocarcinoma must be verified by the treating institution pathologist, from either the initial diagnostic biopsy or from the required pre-treatment biopsy, in order to begin any study-related therapy.
A white blood cell count of 2500 per cubic millimeter or higher is generally considered to be high.
The term "ECOG performance status" refers to a scale that rates the ability of a cancer patient to complete daily tasks
A person has an absolute neutrophil count (ANC) of 1.5 x 109/L without granulocyte colony-stimulating factor support if their ANC is ≥ 1.5 x 109/L and they don't need granulocyte colony-stimulating factor support to maintain their ANC.
Before starting any therapy, confirmation of metastatic (stage IV) disease (unresectable) through a research pretreatment biopsy is required.
requirement in the past 3 days The patient has a platelet count of at least 100,000/uL without the need for a transfusion in the past three days.
The text discusses the histological or pathological confirmation of metastatic pancreatic adenocarcinoma
Patients who have pancreatic cancer that began in the endocrine cells or the acinar cells are not eligible to participate in the study.
Lymphocyte count is at least 500/uL.